By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Retrophin, Inc. 

777 Third Avenue
22nd Floor
New York  New York  10017  U.S.A.
Phone: 646-564–3680 Fax:


SEARCH JOBS

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®.

YEAR FOUNDED:

February 8, 2008

LEADERSHIP:

Founder: Martin Shkreli

CEO: Stephen Aselage

CFO: Laura Clague

JOBS:

Please click here for Retrophin job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.

PRODUCTS:

All Products


Key Statistics


Email: info@retrophin.com
Ownership: Public

Web Site: Retrophin
Employees:
Symbol: RTRX
 



Industry
Biotechnology






Company News
Ligand (LGND) Partner Retrophin (RTRX) Reports Additional Positive Data From Phase 2 DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At American Society of Nephrology Kidney Week 2016 11/21/2016 12:13:53 PM
Retrophin (RTRX) Reports Additional Positive Data From Phase II DUET Study Of Sparsentan In Focal Segmental Glomerulosclerosis At American Society of Nephrology Kidney Week 2016 11/21/2016 10:42:15 AM
Retrophin (RTRX) Reaches Agreement With FDA Under Special Protocol Assessment For Pivotal Trial Evaluating RE-024 In PKAN 11/11/2016 11:06:47 AM
Retrophin (RTRX) Reports Third Quarter 2016 Financial Results 11/4/2016 10:32:45 AM
Retrophin (RTRX) To Report Third Quarter 2016 Financial Results 10/21/2016 8:09:15 AM
Retrophin (RTRX)'s R&D Head Resigns to Helm Unnamed Biotech Startup 10/6/2016 6:14:12 PM
Retrophin (RTRX) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 10/3/2016 8:13:52 AM
Retrophin (RTRX) To Present At The Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series 9/15/2016 8:58:21 AM
Ligand (LGND) Partner Retrophin (RTRX) Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis 9/7/2016 10:57:38 AM
Retrophin (RTRX) Announces Positive Top-Line Results From Phase II DUET Study Of Sparsentan In Patients With Focal Segmental Glomerulosclerosis 9/7/2016 10:02:05 AM
12345678910
//-->